-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JJK4J9LGrPxMrxrrnA+MOvAGhkimNFW+Hf2Ba3TFN+NICYm6i/fVr+wgkz1HAWYP 0GsM9/965gJaiMWhwcRqGw== 0000835887-06-000022.txt : 20060307 0000835887-06-000022.hdr.sgml : 20060307 20060307140448 ACCESSION NUMBER: 0000835887-06-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060303 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20060307 DATE AS OF CHANGE: 20060307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000835887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133379479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23143 FILM NUMBER: 06669640 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9147892800 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 8-K 1 form8kmaddon.htm PROGENICS FORM 8-K MADDON SALARY 3 3 06 Progenics Form 8-K Maddon salary 3 3 06
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) March 3, 2006
 
 
Progenics Pharmaceuticals, Inc.
 
 
 
 
 
(Exact name of registrant as specified in its charter)
 

 
Delaware
 
000-23143
 
13-3379479
 
 
  
 
  
 
  
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
 
777 Old Saw Mill River Road, Tarrytown, New York
10591
 
 
(Address of principal executive offices)
(Zip Code)
     
 
Registrant's telephone number, including area code (914) 789-2800 
 
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
           o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
           o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
           o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))
 
 
           o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act    (17 CFR 240.13e-4(c))
 

 
 
 
Section 1 - Registrant’s Business and Operations
 
 
Item 1.01 Entry into a Material Definitive Agreement.
 
 
On March 3, 2006, the Compensation Committee of the Board of Directors of Progenics Pharmaceuticals, Inc. approved a salary increase for the year ending December 31, 2006 for Paul J. Maddon M.D., Ph.D., the Chief Executive Officer and Chief Science Officer of Progenics Pharmaceuticals, Inc. as follows: 2005 salary ¾ $536,785; 2006 salary ¾ $565,000.
 

 
1
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PROGENICS PHARMACEUTICALS, INC.

By:  /s/ Robert A. McKinney      
Robert A. McKinney
Senior Vice President, Finance and Operations
Chief Financial Officer
 
Date: March 7, 2006
 
 
 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----